18:59 , Aug 15, 2018 |  BC Extra  |  Preclinical News

Gene transfer regenerates rod cells, restores light sensitivity in blind mice

Researchers at the Icahn School of Medicine at Mount Sinai developed a gene transfer process to generate rod photoreceptors that restored light sensitivity in mice with congenital blindness. In a paper published Wednesday in Nature, the...
18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting β-catenin in combination with Xtandi enzalutamide could help treat prostate cancer. In tumor samples from prostate cancer patients, levels of β-catenin were higher in...
19:13 , May 18, 2018 |  BC Week In Review  |  Financial News

Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as...
12:01 , May 16, 2018 |  BC Extra  |  Financial News

Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as...
23:11 , Mar 7, 2018 |  BC Extra  |  Preclinical News

Selectively inhibiting GSK3's double genes for AML

Researchers at the Broad Institute of MIT and Harvard and colleagues found a way to design highly selective glycogen synthase kinase 3 inhibitors that target one of two forms of the gene. The approach could...
23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications study...
19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination and...
18:16 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture studies suggest a stapled peptide inhibitor of the CTNNB1-TCF4 interaction could help treat colorectal cancer. The compound consisted of a stapled peptide that inhibits the CTNNB1-TCF4 interaction, modified with six homo-arginine...
18:24 , Jun 22, 2017 |  BC Innovations  |  Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling, the group showed cancer cells undergoing ER stress send soluble...
23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc., Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...